Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design

被引:18
作者
Wijesundara, Danushka Kumara [1 ,2 ]
Xi, Yang [3 ]
Ranasinghe, Charani [2 ]
机构
[1] Univ Adelaide, Basil Hetzel Inst, Dept Surg, Virol Lab, Adelaide, SA, Australia
[2] Australian Natl Univ, John Curtin Sch Med Res, Mol Mucosal Vaccine Immunol Grp, Canberra, ACT, Australia
[3] Univ Queensland, UQ Sch Med, Translat Res Inst, Lung & Allergy Res Ctr, Woolloongabba, Qld, Australia
来源
FRONTIERS IN IMMUNOLOGY | 2014年 / 5卷
基金
英国医学研究理事会;
关键词
type I interferons; human immunodeficiency virus; IFN-epsilon; vaccine adjuvants; interferon immunity; PLASMACYTOID DENDRITIC CELLS; HUMAN-LEUKOCYTE INTERFERON; CD8; T-CELLS; VIRUS-INFECTION; NEGATIVE REGULATORS; ANTIVIRAL ACTIVITY; IL-10; PRODUCTION; FAMILY PROTEINS; HIV-INFECTION; MOUSE MODEL;
D O I
10.3389/fimmu.2014.00412
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
It has been well-established that type I interferons (IFN-Is) have pleiotropic effects and play an early central role in the control of many acute viral infections. However, their pleiotropic effects are not always beneficial to the host and in fact several reports suggest that the induction of IFN-Is exacerbate disease outcomes against some bacterial and chronic viral infections. In this brief review, we probe into this mystery and try to develop answers based on past and recent studies evaluating the roles of IFN-Is in infection and immunity as this is vital for developing effective IFN-Is based therapeutics and vaccines. We also discuss the biological roles of an emerging IFN-I, namely IFN-epsilon, and discuss its potential use as a mucosal therapeutic and/or vaccine adjuvant. Overall, we anticipate the discussions generated in this review will provide new insights for better exploiting the biological functions of IFN-Is in developing efficacious therapeutics and vaccines in the future.
引用
收藏
页数:7
相关论文
共 119 条
[1]  
Adolf G R, 1995, Mult Scler, V1 Suppl 1, pS44
[2]   Type I Interferons trigger systemic, partial lymphocyte activation in response to viral infection [J].
Alsharifi, M ;
Lobigs, M ;
Regner, M ;
Lee, E ;
Koskinen, A ;
Müllbacher, A .
JOURNAL OF IMMUNOLOGY, 2005, 175 (07) :4635-4640
[3]   Exhaustion of type I interferon response following an acute viral infection [J].
Alsharifi, Mohammed ;
Regner, Matthias ;
Blanden, Robert ;
Lobigs, Mario ;
Lee, Eva ;
Koskinen, Aulikki ;
Mullbacher, Arno .
JOURNAL OF IMMUNOLOGY, 2006, 177 (05) :3235-3241
[4]   STING-Dependent Type I IFN Production Inhibits CellMediated Immunity to Listeria monocytogenes [J].
Archer, Kristina A. ;
Durack, Juliana ;
Portnoy, Daniel A. .
PLOS PATHOGENS, 2014, 10 (01)
[5]   Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes [J].
Auerbuch, V ;
Brockstedt, DG ;
Meyer-Morse, N ;
O'Riordan, M ;
Portnoy, DA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (04) :527-533
[6]   Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration [J].
Azzoni, Livio ;
Foulkes, Andrea S. ;
Papasavvas, Emmanouil ;
Mexas, Angela M. ;
Lynn, Kenneth M. ;
Mounzer, Karam ;
Tebas, Pablo ;
Jacobson, Jeffrey M. ;
Frank, Ian ;
Busch, Michael P. ;
Deeks, Steven G. ;
Carrington, Mary ;
O'Doherty, Una ;
Kostman, Jay ;
Montaner, Luis J. .
JOURNAL OF INFECTIOUS DISEASES, 2013, 207 (02) :213-222
[7]  
Baker Danial E, 2003, Rev Gastroenterol Disord, V3, P93
[8]   Type I interferon in systemic lupus erythematosus and other autoimmune diseases [J].
Banchereau, Jacques ;
Pascual, Virginia .
IMMUNITY, 2006, 25 (03) :383-392
[9]   Restoring function in exhausted CD8 T cells during chronic viral infection [J].
Barber, DL ;
Wherry, EJ ;
Masopust, D ;
Zhu, BG ;
Allison, JP ;
Sharpe, AH ;
Freeman, GJ ;
Ahmed, R .
NATURE, 2006, 439 (7077) :682-687
[10]   The interferon response inhibits HIV particle production by induction of TRIM22 [J].
Barr, Stephen D. ;
Smiley, James R. ;
Bushman, Frederic D. .
PLOS PATHOGENS, 2008, 4 (02)